Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/21/2021 | $14.00 | Buy | Brookline Capital |
| 9/14/2021 | $9.00 | Buy | Maxim Group |
Brookline Capital initiated coverage of Dermata Therapeutics with a rating of Buy and set a new price target of $14.00
Maxim Group initiated coverage of Dermata Therapeutics with a rating of Buy and set a new price target of $9.00
8-K - Dermata Therapeutics, Inc. (0001853816) (Filer)
8-K - Dermata Therapeutics, Inc. (0001853816) (Filer)
8-K - Dermata Therapeutics, Inc. (0001853816) (Filer)
4 - Dermata Therapeutics, Inc. (0001853816) (Issuer)
4 - Dermata Therapeutics, Inc. (0001853816) (Issuer)
4 - Dermata Therapeutics, Inc. (0001853816) (Issuer)
NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Sciences Virtual Investor Forum, held September 18th are now available for online viewing. REGISTER AND VIEW PRESENTATIONS HERE The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may downloadinvestor materials from the company's resource section. Select companies are accepting 1x1 management meeting requests through September 23. Please schedule 1x1 meetings here September 18th PresentationTicker(s)Amplia Therapeutics Limited(OTC:INNMF, ASX: ATX))Kelyniam Global, Inc.(O
NEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Science Virtual Investor Forum to be held September 18th. This event is co-hosted by Zacks SCR. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates. There is no cost to log-in, attend live presentations, or schedule 1x1 meetings with management. Please schedule 1x1 meetings here "We are excited to highlight today's innovators from the life scienc
SAN DIEGO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Dermata Therapeutics to Present at the Life Sciences Virtual Investor Forum September 18th Dermata invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com San Diego, CA, September 16, 2025 -- Dermata Therapeutics, Inc. (NASDAQ:DRMA, DRMAW)) ("Dermata" or the "Company"), a science-driven leader in dermatologic solutions, today announced that Gerry Proehl, Founder and CEO of Dermata, will present live at the Life Sciences Virtual Investor Forum hosted by VirtualInvestorConferences.com, on September 18th, 2025. DATE: September 18th TIME: 11:30 AM ESTLINK: REGISTER HERE
SAN DIEGO, CA / ACCESSWIRE / January 13, 2022 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata," or the "Company"), a clinical-stage biotechnology company focused on the treatment of medical and aesthetic skin conditions, today announced the appointment of Brittany Bradrick to its Board of Directors and its Audit Committee."I am excited to welcome Brittany to our Board of Directors," commented Gerry Proehl, Dermata's Chief Executive Officer, President, and Chairman. "Brittany brings an immense amount of industry expertise to Dermata and has an accomplished background with over 25 years' experience in finance, strategy, and corporate development for life science companies, with both opera
SAN DIEGO, CA / ACCESSWIRE / September 1, 2021 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA)(NASDAQ:DRMAW), a clinical-stage biopharmaceutical company focused on the development of novel dermatology therapies, today announced the appointment of Kyri Van Hoose as Senior Vice President, Chief Financial Officer. Ms. Van Hoose is a strategic and operational finance leader with over 20 years of experience, including more than 15 years in the life sciences industry. Ms. Van Hoose is replacing Thomas Insley, who is retiring as the Company's full time CFO after 6 years, but will continue to work with the Company as a financial consultant."I am very excited to welcome Kyri
- End of Phase 2 meeting with FDA for DMT310 for moderate-to-severe acne expected in 2Q 2023 -- Initiation of DMT310 Phase 3 clinical trial program in moderate-to-severe acne patients expected in 2H 2023 -- DMT410 partnering discussions ongoing -SAN DIEGO, CA / ACCESSWIRE / February 21, 2023 / Dermata Therapeutics, Inc. (NASDAQ:DRMA, DRMAW))) ("Dermata," or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today highlighted recent corporate progress, and reported financial results for the year ended December 31, 2022."We are very excited for what Dermata has planned for 2023 for both our DMT310 and DMT410 programs," sai
- DMT310 Phase 2 topline results in moderate-to-severe rosacea anticipated in December 2022 -- Initiation of DMT310 Phase 3 for moderate-to-severe acne expected in 1H 2023 -SAN DIEGO, CA / ACCESSWIRE / November 10, 2022 / Dermata Therapeutics, Inc. (NASDAQ:DRMA, DRMAW))) ("Dermata," or the "Company"), a clinical-stage biopharmaceutical company focusing on the treatment of medical and aesthetic skin conditions, today highlighted recent corporate progress, and reported financial results for the quarter ended September 30, 2022."I am thrilled with all that Dermata has accomplished so far this year and plan to continue the momentum as we near the announcement of our DMT310 Phase 2 topline result
SC 13G/A - Dermata Therapeutics, Inc. (0001853816) (Subject)
SC 13G - Dermata Therapeutics, Inc. (0001853816) (Subject)
SC 13G - Dermata Therapeutics, Inc. (0001853816) (Subject)